Funder: Alzheimer's Association
Due Dates (Anticipated): August 2026 (Letter of Intent) | September 2026 (Full application)
Funding Amounts: Up to $1,000,000 total (direct + indirect) over 2–3 years; indirect costs capped at 10% for nonprofits, none for for-profits.
Summary: Supports early-phase clinical trials of novel or repurposed therapies for Alzheimer’s disease to bridge the gap between preclinical research and larger efficacy studies.
Key Information: Forecasted dates—check program page for updates; open to U.S. and international applicants.